These in vitro results, indicating that IL-10 production can be enhanced by GBZ, confirmed that our strategy of targeting eIF2α phosphorylation to limit systemic inflammation and liver failure during endotoxemia was appropriate. This evidence concerns the gene EIF2A and serum lipopolysaccharide activity.